178 related articles for article (PubMed ID: 24766460)
1. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.
Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC
Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
3. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
4. Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018.
Bartoli F; Bae S; Cometi L; Matucci Cerinic M; Furst DE
Expert Rev Clin Immunol; 2018 Jul; 14(7):539-547. PubMed ID: 29925278
[TBL] [Abstract][Full Text] [Related]
5. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.
Siebert S; Tsoukas A; Robertson J; McInnes I
Pharmacol Rev; 2015; 67(2):280-309. PubMed ID: 25697599
[TBL] [Abstract][Full Text] [Related]
6. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH
Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633
[TBL] [Abstract][Full Text] [Related]
7. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
Woodrick RS; Ruderman EM
Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapeutics for rheumatoid arthritis.
Bingham CO
Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis.
Mircic M; Kavanaugh A
Exp Cell Res; 2011 May; 317(9):1286-92. PubMed ID: 21439276
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-6 therapy in rheumatoid arthritis.
Woodrick R; Ruderman EM
Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
[TBL] [Abstract][Full Text] [Related]
11. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction].
Perniok A; Rubbert-Roth A
Z Rheumatol; 2003 Oct; 62(5):433-8. PubMed ID: 14579030
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
[TBL] [Abstract][Full Text] [Related]
13. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.
June RR; Olsen NJ
Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017
[TBL] [Abstract][Full Text] [Related]
14. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
Avci AB; Feist E; Burmester GR
BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
[TBL] [Abstract][Full Text] [Related]
15. Targeting interleukin-6 in rheumatoid arthritis.
Md Yusof MY; Emery P
Drugs; 2013 Mar; 73(4):341-56. PubMed ID: 23456676
[TBL] [Abstract][Full Text] [Related]
16. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
Narazaki M; Tanaka T; Kishimoto T
Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
[TBL] [Abstract][Full Text] [Related]
17. [IL-6 inhibitors prevent bone loss and cartilage degeneration in rheumatoid arthritis].
Murakami M; Nishimoto N
Clin Calcium; 2015 Dec; 25(12):1851-7. PubMed ID: 26608861
[TBL] [Abstract][Full Text] [Related]
18. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
Smolen JS; Schoels MM; Nishimoto N; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Betteridge N; Bingham CO; Bykerk V; Choy EH; Combe B; Cutolo M; Graninger W; Lanas A; Martin-Mola E; Montecucco C; Ostergaard M; Pavelka K; Rubbert-Roth A; Sattar N; Scholte-Voshaar M; Tanaka Y; Trauner M; Valentini G; Winthrop KL; de Wit M; van der Heijde D
Ann Rheum Dis; 2013 Apr; 72(4):482-92. PubMed ID: 23172750
[TBL] [Abstract][Full Text] [Related]
19. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis.
Semerano L; Assier E; Delavallée L; Boissier MC
Expert Opin Biol Ther; 2011 Apr; 11(4):545-50. PubMed ID: 21385114
[TBL] [Abstract][Full Text] [Related]
20. Biological therapies for rheumatoid arthritis: progress to date.
Malviya G; Salemi S; Laganà B; Diamanti AP; D'Amelio R; Signore A
BioDrugs; 2013 Aug; 27(4):329-45. PubMed ID: 23558378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
